Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals, Peptide drug conjugates |
Synonyms 177 Lu-RAYZ-8009, 177Lu RAYZ-8009, 177Lu-RAYZ-8009 + [5] |
Target |
Mechanism GPC3 modulators(Glypican-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | US | Rayzebio, Inc.Startup | 22 Apr 2020 |
Hepatocellular Carcinoma | Preclinical | CN | 22 Apr 2020 | |
Hepatocellular Carcinoma | Preclinical | JP | 22 Apr 2020 |